Mehmet H. Kural

Mehmet H. Kural

Auto-generated profile, based on publicly available information

Mehmet H. Kural

Worcester Polytechnic Institute, Worcester, MA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Circulation Research
Verified
Journal Article
Open access
PDF file
KNKaleb M. Naegeli
Kaleb M. Naegeli
MKMehmet H. Kural
Mehmet H. Kural
YLYuling Li
Yuling Li
JWJuan Wang
Juan Wang
EHEmmanuelle A. Hugentobler
Emmanuelle A. Hugentobler
LNLaura E. Niklason
Laura E. Niklason
Cardiovascular defects, injuries, and degenerative diseases often require surgical intervention and the use of implantable replacement material and conduits. Traditional vascular grafts made of synthetic polymers, animal and cadaveric tissues, or autologous vasculature have been utilized for almost a century with well-characterized outcomes, leaving areas of unmet need for the patients in terms of durability and long-term patency, susceptibility to infection, immunogenicity associated with the risk of rejection, and inflammation and mechanical failure. Research to address these limitations is exploring avenues as diverse as gene therapy, cell therapy, cell reprogramming, and bioengineering of human tissue and replacement organs. Tissue-engineered vascular conduits, either with viable autologous cells or decellularized, are the forefront of technology in cardiovascular reconstruction and offer many benefits over traditional graft materials, particularly in the potential for the implanted material to be adopted and remodeled into host tissue and thus offer safer, more durable performance. This review discusses the key advances and future directions in the field of surgical vascular repair, replacement, and reconstruction, with a focus on the challenges and expected benefits of bioengineering human tissues and blood vessels.

1 January 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
JPJinkyu Park
Jinkyu Park
CAChristopher W. Anderson
Christopher W. Anderson
LSLorenzo R. Sewanan
Lorenzo R. Sewanan
MKMehmet H. Kural
Mehmet H. Kural
YHYan Huang
Yan Huang
YQYibing Qyang
Yibing Qyang

1 March 2016 in Acta Biomaterialia
Verified
Journal Article
Closed access
MKMehmet H. Kural
Mehmet H. Kural
KBKristen L. Billiar
Kristen L. Billiar

29 May 2021 in Biomaterials
Verified
Journal Article
Closed access
JWJuan Wang
Juan Wang
MKMehmet H. Kural
Mehmet H. Kural
JWJonathan Wu
Jonathan Wu
KLKatherine L. Leiby
Katherine L. Leiby
VMVinayak Mishra
Vinayak Mishra
LNLaura E. Niklason
Laura E. Niklason

1 January 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
JLJiesi Luo
Jiesi Luo
YLYuyao Lin
Yuyao Lin
XSXiangyu Shi
Xiangyu Shi
GLGuangxin Li
Guangxin Li
MKMehmet H. Kural
Mehmet H. Kural
YQYibing Qyang
Yibing Qyang

22 June 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MKMehmet H. Kural
Mehmet H. Kural
UDUmidahan Djakbarova
Umidahan Djakbarova
BCBilal Cakir
Bilal Cakir
YTYoshiaki Tanaka
Yoshiaki Tanaka
ECEmily T. Chan
Emily T. Chan
CKCömert Kural
Cömert Kural
The transmembrane death receptor Fas transduces apoptotic signals upon binding its ligand, FasL. Although Fas is highly expressed in cancer cells, insufficient cell surface Fas expression desensitizes cancer cells to Fas-induced apoptosis. Here, we show that the increase in Fas microaggregate formation on the plasma membrane in response to the inhibition of endocytosis sensitizes cancer cells to Fas-induced apoptosis. We used a clinically accessible Rho-kinase inhibitor, fasudil, that reduces endocytosis dynamics by increasing plasma membrane tension. In combination with exogenous soluble FasL (sFasL), fasudil promoted cancer cell apoptosis, but this collaborative effect was substantially weaker in nonmalignant cells. The combination of sFasL and fasudil prevented glioblastoma cell growth in embryonic stem cell-derived brain organoids and induced tumor regression in a xenograft mouse model. Our results demonstrate that sFasL has strong potential for apoptosis-directed cancer therapy when Fas microaggregate formation is augmented by mechano-inhibition of endocytosis.